Carcinosarcoma (Metaplastic Carcinoma) Breast: A Rare and Aggressive Primary – Report of Two Cases with Review of Literature

Gunjesh Kumar Singh; Pragya Singh; KT Bhowmik

doi:10.4103/ijmpo.ijmpo_27_17

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(03): 400-404
DOI: 10.4103/ijmpo.ijmpo_27_17

Case Report

Carcinosarcoma (Metaplastic Carcinoma) Breast: A Rare and Aggressive Primary – Report of Two Cases with Review of Literature

Gunjesh Kumar Singh

Department of Radiotherapy, VMMC and Safdarjung Hospital, New Delhi, India

,

Pragya Singh

Department of Pathology, VMMC and Safdarjung Hospital, New Delhi, India

,

KT Bhowmik

Department of Radiotherapy, VMMC and Safdarjung Hospital, New Delhi, India

› Institutsangaben

Abstract

Carcinosarcoma (CS) also known as metaplastic carcinoma of the breast is a rare and aggressive type of malignancy with controversial origin. Currently, there are no standard treatment guidelines outlined, owing to the rarity of the disease, but according to the available literature, surgery followed by adjuvant radiation therapy has the greatest benefit. We are presenting two cases of CS of breast developing metastasis. One of the cases presented with lung metastasis during the course of follow-up and responded significantly to chemotherapy, and the other is currently receiving chemotherapy. The cases are being presented here along with the literature review enlightening the current knowledge and available treatment options.

Keywords

Carcinosarcoma breast - chemotherapy - metaplastic carcinoma

Volltext

Referenzen

References
1 Srinivas V, Harjai MM, Subramanya H, Rajaram T, Rai R. Carcinosarcoma of the breast with an unusual secretory carcinoma as the carcinomatous component. Med J Armed Forces India 2004; 60: 410-2
2 Accurso A, Ciancia G, Della Corte GA, Reale P, Accardo G, Salerno C. et al. A rare case of true carcinosarcoma of the breast. Int J Surg Case Rep 2016; 21: 125-8
3 Ilhan E, Vardar E, Ozkok G, Sezgin A, Sahin S, Teker K. et al. A rare tumour of the breast: Carcinosarcoma. J Clin Med Res 2016; 2: 96-8
4 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M. et al. incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86
5 Kim SH, Chung HC, Jeong J, Kim JH, Rha SY, Ahn JB. et al. A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: A case report. Cancer Res Treat 2007; 39: 134-7
6 Huvos AG, Lucas JCJr, Foote FWJr. Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med 1973; 73: 1078-82
7 Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: Clinical significance. Am J Surg 2006; 191: 657-64
8 Shin HJ, Kim HH, Kim SM, Kim DB, Kim MJ, Gong G. et al. Imaging features of metaplastic carcinoma with chondroid differentiation of the breast. AJR Am J Roentgenol 2007; 188: 691-6
9 Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA. et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: The experience of the European institute of oncology and review of the literature. Breast Cancer Res Treat 2007; 101: 349-53
10 McKinnon E, Xiao P. Metaplastic carcinoma of the breast. Arch Pathol Lab Med 2015; 139: 819-22
11 Cil T, Altintas A, Pasa S, Buyukbayram H, Isikdogan A. Primary spindle cell sarcoma of the breast. Breast Care (Basel) 2008; 3: 197-9
12 Abbasi MA, Mahmood H, Faheem M, Khan KA, Irfan J. Carcinosarcoma of the breast. J Coll Physicians Surg Pak 2012; 22: 333-4
13 Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast III Carcinosarcoma. Cancer 1989; 64: 1490-9
14 Sørlie T. Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40: 2667-75
15 Esses KM, Hagmaier RM, Blanchard SA, Lazarchick JJ, Riker AI. Carcinosarcoma of the breast: Two case reports and review of the literature. Cases J 2009; 2: 15
16 Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS. et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69: 4116-24
17 Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K. et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006; 209: 445-53
18 Gurleyik E, Yildirim U, Gunal O, Pehlivan M. Malignant mesenchymal tumor of the breast: Primary chondrosarcoma. Breast Care (Basel) 2009; 4: 101-3
19 Pope TLJr, Fechner RE, Brenbridge AN. Carcinosarcoma of the breast: Radiologic, ultrasonographic, and pathologic correlation. Can Assoc Radiol J 1987; 38: 50-1
20 Shah DR, Tseng WH, Martinez SR. Treatment options for metaplastic breast cancer. ISRN Oncol 2012; 2012: 706162
21 Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ. et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: The national cancer institute randomized trial. Cancer 2003; 98: 697-702
22 Lai WH, Tseng LM, Chang TW, Kuo YL, Hsieh CM, Chen ST. et al. The prognostic significance of metaplastic carcinoma of the breast (MCB) – A case controlled comparison study with infiltrating ductal carcinoma. Breast 2013; 22: 968-73
23 Dave G, Cosmatos H, Do T, Lodin K, Varshney D. Metaplastic carcinoma of the breast: A retrospective review. Int J Radiat Oncol Biol Phys 2006; 64: 771-5
24 Buzdar AU, Valero V, Theriault RL, Frye D, Green M, Booser D. et al. Pathological complete response to chemotherapy is related to hormone receptor status [abstract]. Breast Cancer Res Treat 2003; 85: 2
25 Hennessy BT, Giordano S, Broglio K, Duan Z, Trent J, Buchholz TA. et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 2006; 17: 605-13
26 Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH. et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat 2011; 126: 471-8
27 Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H. et al. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004; 90: 236-44
28 Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for her-2 but frequently express EGFR (Her-1): Potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?. J Clin Pathol 2005; 58: 700-4
29 Weigelt B, Eberle C, Cowell CF, Ng CK, Reis-Filho JS. Metaplastic breast carcinoma: More than a special type. Nat Rev Cancer 2014; 14: 147-8